{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:22:35Z","timestamp":1793866955896,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40266-020-00823-5","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T20:46:24Z","timestamp":1606164384000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of Bullous Pemphigoid in People Aged 80\u00a0Years and Older: A Systematic Review of the Literature"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-8351","authenticated-orcid":false,"given":"Meital","family":"Oren-Shabtai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Lapidoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Atzmony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assi","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"issue":"9863","key":"823_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332.","journal-title":"Lancet"},{"key":"823_CR2","doi-asserted-by":"crossref","unstructured":"Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011;29(3):427\u201338, vii\u2013ix.","DOI":"10.1016\/j.det.2011.03.010"},{"issue":"4","key":"823_CR3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","volume":"18","author":"P Bernard","year":"2017","unstructured":"Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513\u201328.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"823_CR4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"G Marazza","year":"2009","unstructured":"Marazza G, Pham H, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861\u20138.","journal-title":"Br J Dermatol"},{"issue":"7662","key":"823_CR5","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"S Langan","year":"2008","unstructured":"Langan S, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgarise incidence and mortality in the UK: population-based cohort study. BMJ. 2008;337(7662):a180.","journal-title":"BMJ"},{"issue":"8","key":"823_CR6","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Investig Dermatol. 2012;132(8):1998\u20132004.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"823_CR7","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434\u201340.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2 Pt 1","key":"823_CR8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","volume":"41","author":"M Jung","year":"1999","unstructured":"Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"823_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","volume":"150","author":"F Fichel","year":"2014","unstructured":"Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25\u201333.","journal-title":"JAMA Dermatol"},{"key":"823_CR10","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Joly P, Lemordant P et al.; French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case\u2013control study. J Investig Dermatol. 2011;131(3):637\u201343.","DOI":"10.1038\/jid.2010.301"},{"key":"823_CR11","doi-asserted-by":"crossref","unstructured":"Cordel N, Chosidow O, Hellot M-F et al.; French Study Group for Bullous Diseases. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007;215(3):187\u201391.","DOI":"10.1159\/000106574"},{"issue":"9","key":"823_CR12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","volume":"28","author":"PG Stravopoulos","year":"2014","unstructured":"Stravopoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid. J Eur Acad Dermatol Venereol. 2014;28(9):1133\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"823_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00403-013-1399-5","volume":"306","author":"E Ong","year":"2014","unstructured":"Ong E, Goldacre R, Hoang U, et al. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999\u20132011. Arch Dermatol Res. 2014;306(1):75\u201380.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"823_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2133.1979.tb11881.x","volume":"101","author":"JA Savin","year":"1979","unstructured":"Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101(5):521\u201334.","journal-title":"Br J Dermatol"},{"issue":"1","key":"823_CR15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0738-081X(87)90049-6","volume":"5","author":"JA Savin","year":"1987","unstructured":"Savin JA. Death in bullous pemphigoid. Clin Dermatol. 1987;5(1):52\u20139.","journal-title":"Clin Dermatol"},{"issue":"4","key":"823_CR16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","volume":"59","author":"SR Parker","year":"2008","unstructured":"Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59(4):582\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"823_CR17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"VA Venning","year":"2012","unstructured":"Venning VA, Taghipour K, Mohd Mustapa MF, et al. British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200\u201314.","journal-title":"Br J Dermatol"},{"key":"823_CR18","doi-asserted-by":"crossref","unstructured":"Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin N Am. 2012;32(2):283\u201394, vii.","DOI":"10.1016\/j.iac.2012.04.008"},{"key":"823_CR19","doi-asserted-by":"crossref","unstructured":"Joly P, Roujeau JC, Benichou J et al.; Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137.","DOI":"10.1056\/NEJMoa011592"},{"issue":"7","key":"823_CR20","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"P Joly","year":"2009","unstructured":"Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Investig Dermatol. 2009;129(7):1681\u20137.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"823_CR21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European dermatology forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867\u201377.","journal-title":"Br J Dermatol"},{"issue":"10","key":"823_CR22","first-page":"CD002292","volume":"2010","author":"G Kirtschig","year":"2010","unstructured":"Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;2010(10):CD002292.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"823_CR23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.det.2011.06.003","volume":"29","author":"BS Daniel","year":"2011","unstructured":"Daniel BS, Borradori L, Hall RP 3rd, et al. Evidence-based management of bullous pemphigoid. Dermatol Clin. 2011;29(4):613\u201320.","journal-title":"Dermatol Clin"},{"issue":"4","key":"823_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0378-6323.82400","volume":"77","author":"S Singh","year":"2011","unstructured":"Singh S. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Indian J Dermatol Venereol Leprol. 2011;77(4):456\u201369.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"823_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","volume":"20","author":"N Kremer","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209\u201316.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"823_CR26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","volume":"134","author":"J Roujeau","year":"1998","unstructured":"Roujeau J, Lok C, Bastuji-Garin S, Mhalla S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134(4):465\u20139.","journal-title":"Arch Dermatol"},{"issue":"8","key":"823_CR27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.1977.01640080045002","volume":"113","author":"AR Ahmed","year":"1977","unstructured":"Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113(8):1043\u20136.","journal-title":"Arch Dermatol"},{"issue":"4","key":"823_CR28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0190-9622(92)70085-T","volume":"26","author":"VA Venning","year":"1992","unstructured":"Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26(4):585\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"823_CR29","first-page":"1229","volume":"62","author":"P Bernard","year":"1986","unstructured":"Bernard P, Venot J, Rommel A, et al. Bullous pemphigoid: a prognostic study: review of 57 observations [in French]. Semin Hop. 1986;62:1229\u201332.","journal-title":"Semin Hop"},{"issue":"5 Pt 1","key":"823_CR30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0190-9622(90)70111-T","volume":"22","author":"A Milligan","year":"1990","unstructured":"Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol. 1990;22(5 Pt 1):796\u2013801.","journal-title":"J Am Acad Dermatol"},{"key":"823_CR31","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"3","key":"823_CR32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479\u201385.","journal-title":"J Am Acad Dermatol"},{"key":"823_CR33","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"823_CR34","unstructured":"Wells GA, Shea B, O\u2019Connel D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed 5 May 2020."},{"issue":"6","key":"823_CR35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","volume":"45","author":"AR Ahmed","year":"2001","unstructured":"Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(6):825\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"823_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2133.1995.tb02631.x","volume":"133","author":"RC Beckers","year":"1995","unstructured":"Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol. 1995;133(2):289\u201393.","journal-title":"Br J Dermatol"},{"issue":"1","key":"823_CR37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","volume":"173","author":"YT Cho","year":"2015","unstructured":"Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173(1):302\u20134.","journal-title":"Br J Dermatol"},{"issue":"5","key":"823_CR38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","volume":"122","author":"RL Colbert","year":"2004","unstructured":"Colbert RL, Allen DM, Eastwood D, et al. Mortality rate of bullous pemphigoid in a US Medical Center. J Investig Dermatol. 2004;122(5):1091\u20135.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"823_CR39","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","volume":"165","author":"A Du-Thanh","year":"2011","unstructured":"Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337\u201343.","journal-title":"Br J Dermatol"},{"issue":"6","key":"823_CR40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","volume":"130","author":"DP Fivenson","year":"1994","unstructured":"Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753\u20138.","journal-title":"Arch Dermatol"},{"issue":"6 Pt 1","key":"823_CR41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0190-9622(99)70084-8","volume":"40","author":"M Grundmann-Kollmann","year":"1999","unstructured":"Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"823_CR42","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jdv.12155","volume":"28","author":"A Gual","year":"2014","unstructured":"Gual A, Iranzo P, Mascar\u00f5 JM. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol Venereol. 2014;28(6):814\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"823_CR43","first-page":"1109","volume":"16","author":"F H\u00fcbner","year":"2018","unstructured":"H\u00fcbner F, Kasperkiewicz M, Knuth-Rehr D, et al. Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges. 2018;16(9):1109\u201318.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"823_CR44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1346-8138.2004.tb00689.x","volume":"31","author":"T Izumi","year":"2004","unstructured":"Izumi T, Ichiki Y, Esaki C, et al. Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. J Dermatol. 2004;31(5):383\u201391.","journal-title":"J Dermatol"},{"issue":"6146","key":"823_CR45","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","volume":"2","author":"JL Burton","year":"1978","unstructured":"Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2(6146):1190\u20131.","journal-title":"Br Med J"},{"issue":"3","key":"823_CR46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1346-8138.14173","volume":"45","author":"R Kakuta","year":"2018","unstructured":"Kakuta R, Yamagami J, Funakoshi T, et al. Azathioprine monotherapy in autoimmune blistering diseases: a feasible option for mild to moderate cases. J Dermatol. 2018;45(3):334\u20139.","journal-title":"J Dermatol"},{"issue":"1","key":"823_CR47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2133.1995.tb02498.x","volume":"133","author":"DN Kolbach","year":"2006","unstructured":"Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 2006;133(1):88\u201390.","journal-title":"Br J Dermatol"},{"issue":"5","key":"823_CR48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2230.2001.00838.x","volume":"26","author":"WJ Loo","year":"2001","unstructured":"Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol. 2001;26(5):376\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"823_CR49","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","volume":"25","author":"S Lourari","year":"2011","unstructured":"Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25(10):1238\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"823_CR50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/09546630600964999","volume":"17","author":"AV Marzano","year":"2006","unstructured":"Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatol Treat. 2006;17(6):370\u20136.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"823_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2015.01.013","volume":"78","author":"R Moriuchi","year":"2015","unstructured":"Moriuchi R, Nishie W, Ujiie H, et al. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases. J Dermatol Sci. 2015;78(1):21\u20135.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"823_CR52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1346-8138.1996.tb02681.x","volume":"23","author":"T Muramatsu","year":"1996","unstructured":"Muramatsu T, Iida T, Shirai T. Pemphigoid and pemphigus foliaceus successfully treated with topical corticosteroids. J Dermatol. 1996;23(10):683\u20138.","journal-title":"J Dermatol"},{"issue":"9","key":"823_CR53","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","volume":"138","author":"O Dereure","year":"2002","unstructured":"Dereure O, Bessis D, Guillot B, et al. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol. 2002;138(9):1255\u20136.","journal-title":"Arch Dermatol"},{"issue":"4","key":"823_CR54","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(94)70227-6","volume":"31","author":"MA Paul","year":"1994","unstructured":"Paul MA, Jorizzo JL, Fleischer AB, et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31(4):620\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"823_CR55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174\u20138.","journal-title":"Arch Dermatol"},{"issue":"6","key":"823_CR56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dth.12403","volume":"29","author":"R Schneiderbauer","year":"2016","unstructured":"Schneiderbauer R, Martinache S, Engstner M, et al. Correlation of autoantibodies against BP180\/BP230 in response to topical corticosteroids in patients with bullous pemphigoid. Dermatol Ther. 2016;29(6):419\u201323.","journal-title":"Dermatol Ther"},{"issue":"2","key":"823_CR57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1468-3083.2004.00870.x","volume":"18","author":"A Stockman","year":"2004","unstructured":"Stockman A, Beele H, Vanderhaeghen Y, et al. Topical class I corticosteroids in 10 patients with bullous pemphigoid: correlation of the outcome with the severity degree of the disease and review of the literature. J Eur Acad Dermatol Venereol. 2004;18(2):164\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"823_CR58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0190-9622(93)70013-J","volume":"28","author":"I Thomas","year":"1993","unstructured":"Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol. 1993;28(1):74\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"823_CR59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","volume":"120","author":"VA Venning","year":"1989","unstructured":"Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120(1):83\u201392.","journal-title":"Br J Dermatol"},{"issue":"2","key":"823_CR60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000018090","volume":"198","author":"U Wollina","year":"1999","unstructured":"Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology. 1999;198(2):140\u20134.","journal-title":"Dermatology"},{"issue":"3","key":"823_CR61","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"823_CR62","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bjd.14285","volume":"174","author":"V Sobocinski","year":"2016","unstructured":"Sobocinski V, Duvert-Lehembre S, Bubenheim M, et al. Assessment of adherence to topical corticosteroids in patients with bullous pemphigoid. Br J Dermatol. 2016;174(4):919\u201321.","journal-title":"Br J Dermatol"},{"key":"823_CR63","doi-asserted-by":"crossref","unstructured":"Williams HC, Wojnarowska F, Kirtschig G et al.; UK Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomized controlled trial. Lancet. 2017;389(10079):1630\u20138.","DOI":"10.1016\/S0140-6736(17)30560-3"},{"issue":"12","key":"823_CR64","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/11319530-000000000-00000","volume":"26","author":"J Jyrkk\u00e4","year":"2009","unstructured":"Jyrkk\u00e4 J, Enlund H, Korhonen MJ, et al. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039\u201348.","journal-title":"Drugs Aging"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00823-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-020-00823-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00823-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:22:03Z","timestamp":1628601723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-020-00823-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00823-5","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Meital Oren-Shabtai, Noa Kremer, Moshe Lapidoth, Eran Sharon, Lihi Atzmony, Adi Nosrati, Emmilia Hodak, Daniel Mimouni, and Assi Levi have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the gathering and writing of this article: MO-S, NK, DM, and AL designed the study and wrote the first draft of the manuscript. MO-S, NK, and AN gathered and organized the information for this study. MO-S, LA, DM, and AL analyzed the gathered data. ML, ES, and EH revised the paper and added important insights critical to its final form.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}